CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma - Trial NCT05458180
Access comprehensive clinical trial information for NCT05458180 through Pure Global AI's free database. This Phase 1 trial is sponsored by Tianjin Medical University Cancer Institute and Hospital and is currently Not yet recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 18 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)
Interventional
drug
Sponsor & Location
Tianjin Medical University Cancer Institute and Hospital
Timeline & Enrollment
Phase 1
Jul 07, 2022
Apr 15, 2025
Primary Outcome
Maximum tolerated dose (MTD)
Summary
This is a prospective, single arm, multicenter, dose-escalation clinical study to evaluate
 the safety and efficacy of CMOEP in patients with untreated Peripheral T-cell Lymphoma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05458180
Non-Device Trial